TY - JOUR T1 - The 1968 Influenza Pandemic and COVID-19 Outcomes JF - medRxiv DO - 10.1101/2021.10.23.21265403 SP - 2021.10.23.21265403 AU - Charles A Taylor AU - Christopher Boulos AU - Matthew J. Memoli Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/14/2021.10.23.21265403.abstract N2 - Past pandemic experience can affect health outcomes in future pandemics. This paper focuses on the last major influenza pandemic in 1968 (H3N2), which killed up to 100,000 people in the US. We find that places with high influenza mortality in 1968 experienced 1-4% lower COVID-19 death rates. Our identification strategy isolates variation in COVID-19 rates across people born before and after 1968. In places with high 1968 influenza incidence, older cohorts experience lower COVID-19 death rates relative to younger ones. The relationship holds using county and patient-level data, as well as in hospital and nursing home settings. Results do not appear to be driven by systemic or policy-related factors, instead suggesting an individual-level response to prior influenza pandemic exposure. The findings merit investigation into potential biological and immunological mechanisms that account for these differences—and their implications for future pandemic preparedness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the COVID-19 Research Database Consortium gave ethical approval for this work. The COVID-19 Research Database was established with IRB approval and an exemption from patient consent due to the use of HIPAA de-identified data, HIPAA limited data or non-HIPAA-covered data, along with the strong governance measures in place to control access to all data. This exemption covers all research performed within the COVID-19 Research Database.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data except for the Healthjump data produced in the present study are available upon reasonable request to the authors. Restrictions apply to the availability of the Healthjump data, which were used under license by the COVID-19 Research Database consortium for the current study, and so are not publicly available. Healthjump data are available with permission of the COVID-19 Research Database consortium. ER -